Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide,

The drugmaker said it would launch late-stage trials of the drug after participants lost as much as 20% of their body weight.

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to prepare to enter phase 3 next month.

A new weight-loss drug from Eli Lilly & Co. helped patients shed as much weight as popular shots like Zepbound, giving the company another edge in the fast-growing obesity market.

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

The Michigan Supreme Court heard oral arguments Wednesday in the state attorney general’s case against insulin-maker Eli Lilly and Company.

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication more accessible nationwide.

Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as more evidence emerges in coming weeks showing that clearing amyloid brain plaques can help patients,